Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06975514

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

A Randomized, Double-blind, Active-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Conditions

Interventions

TypeNameDescription
DRUGYZJ-1139YZJ-1139 20mg tablets, once daily in the evening
DRUGZolpidemZolpidem 10mg tablets, once daily in the evening

Timeline

Start date
2025-03-25
Primary completion
2025-08-01
Completion
2025-09-01
First posted
2025-05-16
Last updated
2025-07-15

Locations

16 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06975514. Inclusion in this directory is not an endorsement.

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder (NCT06975514) · Clinical Trials Directory